euro,

welcome to the board.

"what price and when do you think it is the right time to jump in?"

euro, I don't advise or speculate on those things. There is a wealth of info here and other boards to consider that I am sure will give you enough ammo as to what you feel is right.


"just concern qbout those warrants at 0.10."

The following is intended to update you on where we stand with .10 warrants. The first paragraph below is directly from 10K. The second paragraph is from my e-mail discussion with CEO Rabin.
To summarize, as of approx. one month ago, we had about 117MM .10 warrants that had not yet been exercised. Yes, this will always represent stock pressure until they are chewed up, it also represents CASH directly to ACT coffers. These warrants plus stock issued to investors at discounted pricing is still out there. We are no doubt eating away at this on a daily basis to the extent possible on the volume. It takes time but we are making substantial progress in relieving ourselves of past financing deals and massive share issuance. The 10K of late shows ACT has does some major cleansing and has positioned itself quite well prior to trials or an uplisting if they choose that route. In short, we have some discounted shares to work through yet but a fraction of what we have seen in the past. IMO only, some of the recent pressure when we neared .20 was due to the warrant holders doubling up or close to it..once again, just opinion.

_____________________________________________________________________
(from 10K)
"As of December 31, 2010, on an aggregated basis our debt and preferred stock financings may result in being converted into 6,400,425 shares of our common stock, and warrants and options that may be converted into approximately 183,307,361 shares of our common stock."

(this is info from Rabin)
The above totals about 190MM shares. Warrants have decreased by 50MM since the beginning of the year. That leaves us with 140MM stock options and warrants outstanding..15.8 million options and 123.8 million warrants and debt/preferred shares that can be converted to equity.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61203161

fwiw,


I was hoping as trials draw near the institutions would pick up the pace but so far only the following at 1st qtr end. Grand Total..705,000 shares

HILLSTRUST 3/31/2011 15,000 15,000 New
http://www.nasdaq.com/asp/holdings.asp?symbol=ACTC&selected=ACTC&FormType=Institutional

bball,


I think a few get frustrated and don't realize the tortoise pace of clinical trials and the processes. If some feel the need to blame, I can roll with it. Not a big deal but several mails prompted me to reply....thank you

One more possible scenario which may or may not have some bearing on the EU Orphan approval for hESC.

"In Europe, regulations regarding embryonic stem-cell research differ from country to country. However, a ruling on Mar. 10, 2011, by the European Court of Justice of the European Communities denied patents on ES cells to Oliver Brüstle of the University of Bonn on ethical grounds. The court found that even if cell lines could be established without the destruction of embryos, the commercialization of human embryos was unacceptable, and contrary to public policy. This ruling may push European countries to adopt restrictive policies regarding embryonic stem cells and inhibit the development of ES-based therapies."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61552950

Several of you have indicated through mail you are disappointed with a post I made a while back . First and foremost, these were possible upccoming events based on Rabin's conference call. These were NOT my timeframes and I think the post is very clear on that. I have been here long enough and stated many times I don't put any weight in ACT timeframes. While it is approaching a month since CC, below are some explanations that may help.

#1) IRB approval+clinical trials.gov
Reported reason from Rabin
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61863211

#2)EU Orphan Designation(OMP meeting April 6-7)
Obviously did not receive Orphan approval at April meeting. Maybe had questions that need answering and will possibly be done at May's meeting? Rabin would have to address the reason, I don't know.

#3)Roslin Deal
No update except what was stated at CC(see below)

______________________________________________________________________
(post in question)

possible near term events,

likely near term events based on CC info two weeks ago tomorrow.
Item #1 is the heavy hitter for me as starting trials is what ACT is all about.

1)Info posted to clinicaltrials.gov(will allow recruitment to begin)
(CC quote)
"and we expect their final approval within about two weeks."

2)EU Orphan Designation(OMP meeting April 6-7)
(CC quote)
"We have a preliminary indication that we are likely to receive orphan drug status in Europe, and are about to submit an application in Europe to their version of the FDA, the EMEA, for the same therapy"

3)Roslin Deal
(CC quote)
"This should help us significantly in licensing the cells through our Roslin Cells deal, which we are currently working to finalize"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61660050

mail ?,

Many of these warrants were issued long ago at MUCH higher exercise price(starting at $2.50) and would have terminated at year end of 2010. All are now set at .10 with extended dates. One of many items that will add to the continued pressure on the pps..How very nice for the investor crowd of long ago.

(from S-1)
This prospectus also includes an additional 3,403,320 shares of common stock underlying warrants as follows:


· 29,412 shares of common stock issuable upon exercise of warrants, with an exercise price of $0.10 issued to WRW Investments, L.P., on January 28, 2005, in connection with a $50,000 promissory note financing. The initial termination date of the warrants was December 31, 2010. However, the termination date has been extended to December 31, 2014.


· 28,746 shares of common stock issuable upon exercise of warrants, with an exercise price of $0.10 issued to Anthem Venture Management, LLC (FKA Anthem/CIC Venture Managemen LLC) on January 28, 2005, for legal bills paid on behalf of the Company. The initial termination date of the warrants was December 31, 2010. However, the termination date has been extended to December 31, 2014.


· 31,029 shares of common stock issuable upon exercise of warrants, with an exercise price of $0.10, issued to Anthem Venture Management, LLC (FKA Anthem/CIC Venture Management LLC) on January 28, 2005, for services. The initial termination date of the warrants was December 31, 2010. However, the termination date has been extended to December 31, 2014.


· 61,315 shares of common stock issuable upon exercise of warrants, with an exercise price of $0.10 issued to WRW Investments, L.P., on January 28, 2005, for consulting services. The initial termination date of the warrants was December 31, 2010. However, the termination date has been extended to December 31, 2014.


· 29,412 shares of common stock issuable upon exercise of warrants, with an exercise price of $0.10 issued to WRW Investments, L.P., on January 28, 2005, in connection with a $50,000 financing. The initial termination date of the warrants was December 31, 2010. However, the termination date has been extended to December 31, 2014.


· 649,875 shares of common stock issuable upon exercise of warrants, with an exercise price of $0.10, issued to Public Venture Investors, LLC, on December 30, 2004, for services. The warrants terminate on December 30, 2014.


· 600,000 shares of common stock issuable upon exercise of warrants, with an exercise price of $0.10, issued to Asiate Partners, LLC, on December 30, 2004, for services. The warrants terminate on December 30, 2014.


· 147,059 shares of common stock issuable upon exercise of warrants, with an exercise price of $0.10 issued to Anthem Ventures Fund, L.P., on January 28, 2005, in connection with a $250,000 bridge note. The initial termination date of the warrants was December 31, 2010. However, the termination date has been extended to December 31, 2014.


· 650,000 shares of common stock issuable upon exercise of warrants, with an exercise price of $0.10, issued to William Woodward, on September 6, 2007 for consulting services. The warrants terminate on January 25, 2017.


· 1,176,472 shares of common stock issuable upon exercise of warrants, with an exercise price of $0.10 issued to Anthem Ventures Fund, L.P., on January 28, 2005, in connection with a $2 million financing. The initial termination date of the warrants was December 31, 2010. However, the termination date has been extended to December 31, 2014.

If you tell me who the lead clinic is for sure I can work on it for you:) To my knowledge it hasn't been disclosed. I always figured it might be the Casey Eye Institute in Portland, Oregon (headed by Dr. Peter Francis of the Oregon Health Sciences University); If it is, they had a scheduled meeting yesterday.
http://www.ohsu.edu/xd/research/about/integrity/irb/upload/2011-IRB-Calendar-simple.pdf

interstate,

Any institution that is actively involved in research most likely has an IRB of their own. If you take the four listed below from ACT PR you will find they all have established an IRB. Below are a couple links that will help.

"The sites which are currently under consideration are the Jules Stein Eye Institute at UCLA (headed by Dr. Steven Schwartz); the Casey Eye Institute in Portland, Oregon (headed by Dr. Peter Francis of the Oregon Health Sciences University); the University of Massachusetts Memorial Medical Center in Worcester, Massachusetts (headed by Dr. Shalesh Kaushal, Chair of the Department of Ophthalmology); the UMDNJ – New Jersey Medical School in Newark, New Jersey (headed by Dr. Marco Zarbin, Chair, Institute of Ophthalmology and Visual Science); additional sites may be considered."

Information Sheet Guidance for Institutional Review Boards (IRBs), Clinical Investigators, and Sponsors
http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/GuidancesInformationSheetsandNotices/ucm113709.htm

INSTITUTIONAL REVIEW BOARDS (IRBs):
http://www.childtrends.org/Files/Child_Trends-2008_02_19_Evaluation7IRBs.pdf

Folks, having the registration statement of shares for this or any financing allows the Investor, in this case Socius, to immediately sell the shares they receive if they choose . This is a big deal to the Investor, otherwise they would have unregistered shares and would then be subject to Rule 144 which mandates they hold for 6 months prior to resale, among other things. If shares are NOT registered they must meet "exemptions to registration" prior to sale.
http://www.mofo.com/files/Uploads/Documents/FAQRule144_145.pdf

exactly, no different than the Optimus deal...eom

interstate,


Look at it as an available credit line. We started with $25MM. We have used $4MM so we have $21MM available to us if needed. As always, ACT receives monies and in return we issue shares. Also of note per conversation with Rabin a while back, we could not at this time convert all of the remaining $21MM at once as we do not have the shares to do so, at least not at the current pps. Optimus was set up the same using Series B shares.

This,

Series C Preferred Shares Transaction

The following is a description of an aggregate of 224,062,500 shares which are being registered pursuant to this Registration Statement:

On December 30, 2010 (the “Series C Effective Date”), the Company entered into a securities purchase agreement (the “Series C Purchase Agreement”) with Socius CG II, Ltd., a Bermuda exempted company ( “Socius”). The Company’s entry into the Series C Purchase Agreement was disclosed in the Current Report on Form 8-K filed by the Company with the SEC on December 30, 2010, and a complete copy of the Series C Purchase Agreement was filed as an exhibit to the Current Report on Form 8-K filed by the Company on January 3, 2011. Pursuant to the Series C Purchase Agreement:

· The Company agreed to sell, and Socius agreed to purchase, in one or more purchases from time to time (each such purchase, a “Series C Tranche”) in the Company’s sole discretion (subject to the conditions set forth therein), (i) up to 2,500 shares of Series C Preferred Stock (the “Series C Preferred Shares”) at a purchase price of $10,000 per share, for an aggregate purchase price of up to $25,000,000, and (ii) a two-year warrant (the “Socius Warrant”) obligating Socius to purchase shares of the Company’s common stock (the “Common Stock” ) with an aggregate exercise price equal to 20% of the purchase price paid by Socius for the Series C Preferred Shares sold in each Series C Tranche, at an exercise price per share equal to the closing bid price of the Company’s Common Stock on the date the Company provides notice of such Series C Tranche (the “Series C Tranche Notice”). On each date that the Company delivers a Series C Tranche Notice to Socius, Socius shall also become obligated, pursuant to a right automatically vesting on such Series C Tranche Notice date, to purchase that number of shares of Common Stock (such shares of Common Stock the “Additional Investment Shares”) equal in dollar amount to 100% of the Series C Tranche amount set forth in the Series C Tranche Notice at a price per share equal to the closing bid price of the Common Stock on the Series C Tranche Notice date

initial warrant, initial investment shares and commitment fee based on an approx. .19 bid price I am in the realm of 31MM shares..

Notice of Effectiveness Filed,
http://www.sec.gov/Archives/edgar/data/1140098/999999999511001004/xslEFFECTX01/primary_doc.xml

(these shares will now be issued to Socius)
At the initial closing pursuant to the Series C Purchase Agreement, which occurred on the Closing Date, (i) Socius purchased 400 Preferred Shares and the Company received gross proceeds of $4,000,000 (ii) the Company delivered to Socius an initial warrant (the “Initial Warrant”) obligating Socius to purchase shares of Common Stock with an aggregate purchase price of $800,000.00, which shall be automatically exercisable on the date a registration statement for the resale of all shares of Common Stock issuable pursuant to the Series C Purchase Agreement is declared effective, with delivery of such shares made to Socius on the trading day immediately following the exercise date at a per-share price equal to the closing bid price of the Common Stock on the delivery date, and (iii) Socius became obligated to purchase additional shares of Common Stock equal in aggregate dollar amount to $4,000,000 (the “Initial Investment Shares”), with delivery of such shares made to Socius on the trading day immediately following the date the registration statement is declared effective at a price per share equal to the closing bid price of Common Stock on the delivery date.

· The Company agreed to pay to Socius a commitment fee of $1,250,000 (the “Commitment Fee”), at the earlier of the closing of the first Series C Tranche or the six month anniversary of the Series C Effective Date, payable at the Company’s election in cash or common stock valued at 88% of the volume weighted average price of the Company’s common stock on the five trading days preceding the payment date.

This again is part of the registration of shares for the Socius financing. You have the original S-1, the S-1 Amendments and now the Prospectus.All in an effort to have the SEC declare the registration statement effective. When you add up the non-refundable commitment fee of $1,250,000 and the cost of all filings, it gets expensive.

Prospectus filed,
http://www.sec.gov/Archives/edgar/data/1140098/000101376211001009/form424b3.htm

rumit,

Sinclair does have a "miniature swine model" and evaluates "Subretinal Injection, including Stem Cells".
http://www.sinclairresearch.com/Services/Ophthalmic.aspx

Whether the swine model was used for ACT I have no confirmation of that. Below is all I had on file in regards to Sinclair..

(OCT of 2009)
In June 2009 the Company, along with its collaborators published results of the Long-term Safety and Function of RPE from Human Embryonic Stem Cells in Preclinical Models of Macular Degeneration. In parallel the Company entered into a Master Service Agreement with Sinclair Research of Auxvasse, MO to perform a Biodistribution and Safety/Tumorgenicity Study to further support these results.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=42541514

(April 2010)
The studies were designed to address the FDA’s request for additional data on tumorigenicity and biodistribution. The Company believes that the data will support the FDA granting clearance for the Company to commence the SMD study in humans later this year. The studies were completed in conjunction with Sinclair Research, based in Columbia, Missouri, Charles River Labs, MPI and Althea Labs, which have been the company’s outside independent collaborators on both studies.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49341033

Sinclair Research:
http://www.sinclairresearch.com/AboutUs/Default.aspx

Charles River Labs
http://www.criver.com/en-US/AboutUs/Pages/home.aspx

MPI Research: ACTC has been doing business with these folks for a while.
http://www.mpiresearch.com/About.asp

Althea Labs:?
http://www.altheatech.com./

jtac,


no trial has even started yet. The lead clinic has yet to issue IRB approval. This may happen by end of week and then info for trial(s) will be posted at clinicaltrials.gov hpefully next week sometime. Once that info is posted then the process of recruitment of patients may begin.

EU Orphan designation would appear to fall into one of the following categories as it was not approved at last meeting.


Monthly report
Committee for Orphan Medicinal Products (COMP)
6-7 April 2011

Lists of questions
The COMP adopted 3 lists of questions on initial applications. These applications will be discussed again at the next COMP meeting prior to adoption of the opinion.
Oral hearings
Two oral hearings took place.
Withdrawals of applications for orphan medicinal product designation
The COMP noted that 1 application for orphan medicinal product designation was withdrawn.
Upcoming meetings
The 123rd meeting of the COMP will be held on 4-5 May 2011.
http://www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2011/04/WC500105111.pdf

Hawks,


ACT put protections in place for both Optimus and Socius

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=59284780

rumit,

other than the share number change I haven't had time to scan it. Sometimes it is easier to wait and see if any SEC "Correspondences" pop up..:)

Steve,


At the end of 2010 ACT secured $25MM in funding from Socius.
http://www.advancedcell.com/news-and-media/press-releases/advanced-cell-technology-secures-25-million-funding-commitment/

This funding can be drawn down by ACT whenever it sees fit to do so. ACT has drawn down $4MM to date leaving 21MM available.

ACT/Socius contract requires registration of the ACT common shares to back up this loan commitment.

ACT filed a registration statement on 2-14-2011 for approx 224MM shares based on a .16 exercise price as that was the pps at the time of deal. This registration needs to be declared "effective" by the SEC in order for Socius to be able to sell shares they receive from ACT. The amendments you see filed are to update info and sometimes are updated because the SEC wants something explained or changed.

S-1/A filed, 2nd amendment to registration
http://www.sec.gov/Archives/edgar/data/1140098/000101376211000662/forms1a.htm

dianne,

IMO, the around Easter timeframe would be realistic provided IRB approval is received by next Friday and then adding on the 2-5 business days to process/review.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61561497

US Government Shutdown Would Furlough Most Workers At HHS
http://www.nasdaq.com/aspx/stock-market-news-story.aspx?storyid=201104081320dowjonesdjonline000498&title=us-government-shutdown-would-furlough-most-workers-at-hhs

cty,...confirmed..eom

"If your shares of Advanced Cell Common Stock are held in the name of a broker, bank or other nominee, you will receive instructions from the stockholder of record that you must follow for your shares to be voted. Please follow their instructions carefully. Also, please note that if the stockholder of record of your shares of Advanced Cell Common Stock is a broker, bank or other nominee and you wish to vote in person at the special meeting, you must request a legal proxy from your broker, bank or other nominee that holds your shares and present that proxy and proof of identification at the special meeting."
http://www.sec.gov/Archives/edgar/data/1140098/000114420409038302/v155330_pre14a.htm

Stemcall,


sloppy and vague? You have got to be kidding. It is ACCURATE INFO.
Shareholders of record are the important entities that will receive proxie statements ,dividends and so forth. Check out Microsoft 10K, check out GERON 10K..what do you see? It is not the least bit confusing if you know what "shareholders of record" means, if you don't?..well, then there is probably much more in the 10K that you deem "vague and sloppy"..


We think that the explanation on ACT's 10-K form "As of March 11, 2011, there were approximately 235 shareholders of record of our common stock" is sloppy and vague and we have discussed the matter with their Investor Relations person.

Stemcall,


Tell your boss the 10K number is "shareholders of record", which is correct and much different than the beneficial shareholders.(owners)

Past posts,
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=47909141

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45519282

possible near term events,

likely near term events based on CC info two weeks ago tomorrow.
Item #1 is the heavy hitter for me as starting trials is what ACT is all about.

1)Info posted to clinicaltrials.gov(will allow recruitment to begin)
(CC quote)
"and we expect their final approval within about two weeks."

2)EU Orphan Designation(OMP meeting April 6-7)
(CC quote)
"We have a preliminary indication that we are likely to receive orphan drug status in Europe, and are about to submit an application in Europe to their version of the FDA, the EMEA, for the same therapy"

3)Roslin Deal
(CC quote)
"This should help us significantly in licensing the cells through our Roslin Cells deal, which we are currently working to finalize"

The following question represents a common theme being asked regularly,


"rock, you have followed ACT and their financing/shares for a long time now, can you please explain where we are at now and how it will affect anything going forward?. thanks"

I can say without any hesitation whatsoever that ACT is in the best "shape" I have witnessed in the last 5 years. This is due to the following 3 items.

1)CD Financing: This toxic financing started in the fall of 2005 and we signed up for more in 2006, 2007, 2008 and some in 2009. Money was received up front and paid off monthly in shares. The lower the pps the more shares that were issued each month causing constant pressure on stock. Eliminating this debt was by far the most important and beneficial to Company and shareholders.

2)Lawsuits: Most or all lawsuits of the past and during default period are now over with. Yes, many shares again were issued but removing the liability is huge.

3)Fairness hearing settlements: What these amounted to were pre-settlement agreements with 3rd parties to pay off debt obligations. These settlements accounted for a boat load of shares at very discounted prices.

All of the 3 above made it near impossible for the pps to move upward and sustain itself. These are the very reasons ACT has been a trading stock for the past 5 years. For those who mail me and say they "never have sold a share", well, consider yourself very lucky. To have held everything when ACT was in default tells me some had no idea how close we were to shutting down. I give Caldwell credit for giving the CD holders enough incentives to agree to move forward. That was a very big deal.

How does this change things? Shutting down the continuous flood of shares into the float will eventually make a huge and noticable difference. As each day goes by we will chew up the discounted shares and at some point will mostly deal with buyers/sellers who purchased on the open market. This doesn't happen immediately and will take time to change.

Summary: The cleansing of the toxic financing, lawsuits and debt problems has ACT looking very good right now and light years ahead of how we looked only a year ago. Whether ACT is looking to move to a big board, cut a JV deal or eventually have a buy in partner, this cleansing gives ACT the look of a company that can now move forward which translates into leverage if and when needed. So yes, on all fronts, this was critical for the Company and shareholders in order to move to the next level.

dianne..locks,

has there been any update on the DTC chill since the 10K. like the question/answer forum?..thanks

Monthly and year to date trading volume stats,

March: 218MM

February:132 Million

January:487 Million

Total 1st Qtr 2011...837MM

With float of approx 1.4Billion+ first quarter volume equals approx 60% of float

Market Makers AUTO, ETMM and NITE combined represent on average about 68% of volume in first quarter.

AUTO ranks #1 in volume and has been for 6 months

http://www.otcbb.com/asp/tradeact_mv.asp?SearchBy=issue&Issue=ACTC&SortBy=volume&Month=3-1-2011&IMAGE1.x=12&IMAGE1.y=1

woodrow,



The original WiCell license agreement from 2002 was amended into the WARF/WiCell License of 2007. Both of these agreements are no longer.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58558399

WISC Cell Bank
http://www.wicell.org/index.php?option=com_oscommerce&Itemid=272#human

ACT's lines are listed on the International Stem cell Registry,
(click letter M)
http://www.iscr-admin.com/Default.aspx?Action=select+sc+for+view

fwiw,


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58698628

ClinicalTrials.gov facilitates registration of trials in accordance with the International Committee of Medical Journal Editors (ICMJE) initiative requiring prior entry of clinical trials in a public registry as a condition for publication.

The International Committee of Medical Journal Editors (ICJME) has established a requirement that all clinical trials be entered in a public registry before the onset of patient enrollment, as a condition of consideration for publication.

Why can I not find my trial in ClinicalTrials.gov?
After a protocol record has been entered (or modified) and marked as ‘Complete’, it must be approved and released by a PRS administrator. From the time the record is released, it normally takes between 2 and 5 working days for internal quality assurance review and processing for publication on the ClinicalTrials.gov website.

elk,

while it sounds as if they have no shortage of interest from volunteers I am not real sure much can go forward in the selection process until the IRB protocol is complete as the following info indicates from a PR almost 90 days ago.

"Specific inclusion and exclusion requirements and Investigator contact information will be posted shortly at clinicaltrials.gov. Patients and their caregivers should refer to this source rather than contacting ACT or its representatives."
http://www.advancedcell.com/news-and-media/press-releases/advanced-cell-technology-receives-fda-clearance-for-clinical-trials-using-embryonic-stem-cells-to-tre/

ison,

Based on IRB approval soon and given the CC info below they are looking at approx. 7-10 weeks, at least I read it that way.

(from CC)
"Based on our extensive calendar review, I therefore expect that we will begin both trials relatively contemporaneously, in late May or early to mid June."

dianne,

From March 21 CC transcript,
"We have basically concluded our negotiations for the CRO and data management functions for the trials, and have also completed negotiations of the clinical trial agreement with our lead clinical partner, and I expect to have signature copies of these agreements on my desk in the next few days."

"This lead clinical partner has nearly completed approval work on it's university's institutional review board, which has not raised any significant issues, and we expect their final approval within about two weeks.. Once the approval is received, the trial will be listed on the clinicaltrials.gov database, a service of the NIH. At that time, we will begin officially recruiting patients, though we and our clinical partners have been inundated with requests from patients to participate in the trials."

thanks cty, Some have asked my opinion on this. For now I would say it would be hard to put a positive spin on it.

"The court found that even if cell lines could be established without the destruction of embryos, the commercialization of human embryos was unacceptable, and contrary to public policy. This ruling may push European countries to adopt restrictive policies regarding embryonic stem cells and inhibit the development of ES-based therapies."

Next meeting for possible Orphan desigination approval,
Committee for Orphan Medicinal Products...
6-7 April 2011
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000037.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac0580024c5d&jsenabled=true

Mail ?'s,

Why would anyone believe numbers like that? ACT has already given you a dollar figure they feel represents the dry AMD market and the number of potential afflicted, extrapolating from that isn't real difficult. The number below is 15 times what ACT feels it is, conference call will back that up.

If ACTC were to charge say, 15K for their treatments and 30 million people suffer in US and Europe alone, that would equate to 450 BILLION DOLLARS, JUST FOR THAT TREATMENT ALONE.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61489837

NickFromYuma
With 1.3BILLION shares outstanding and 1.19Billion of those shares as float, scooping up a million shares is a drop in the bucket.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61544469
last reported OS# is 1.507 Billion
Float is approx. 1.44 Billion

fwiw,

Once again, this topic points out others are in the game, although many are not at the brink of trials as ACT is, but always noteworthy to say the least.

Because ACT's money maker trial is dry AMD I try and follow those working towards the same. CellCure(BioTime subsidiary)is developing OpRegen for dry AMD and when TEVA(top 15 Pharma in size) took out an option to develop and commercialize this product last fall it spurred me to ask many questions of Biotime, Teva and CellCure and nothing would indicate to me they need to license a patented technique from ACT or purchase ACT cell lines in pursuing trials.
All of the following are exclusive to CellCure also.
http://escellinternational.co/property.htm